These findings suggest that the tumor-specific T cells responding to ICB treatment are largely dependent on the continuous replenishment of CD8+ T cells from outside the tumor, particularly from the TDLNs (4, 19); however, this replenishment process diminishes as the tumor progression advances. Here, CD8A is linked to neoplasm.